The Ozempic Era Disrupting Medtech and Bariatric Surgery
- Published
- Genre
- News & Current Affairs
External source
lifesciencemarketresearch.com External website
You are viewing the Vahuk Story page. The link above opens the shared source website.
While it might seem unlikely, the stage for this disruption was set during an episode of The Dr. Oz Show. Semaglutide, Novo Nordisk’s GLP-1 receptor agonist, was initially developed for diabetes management and later explored for its potential to treat Alzheimer’s and dementia. However, it was on Dr. Oz’s popular talk show that the weight loss properties of the drug—marketed under the brand name Ozempic—became the focus, sparking a viral craze that would ripple across the healthcare industry.
Community reactions
Karma 19.1
Discussion
0 comments
No comments yet. Be the first to join the discussion.